Association Between Cancer Antigen 15-3 and Haematological Parameters According to Treatment Status in Nigerian Women With Breast Cancer
Current Research in Health Sciences · 21.10.2026 · 4 (2) · 48
DOI: 10.58613/crhs427 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Research in Health Sciences, online erschienen am 21.10.2026. Verfasst von Mieiwari Ibifubara Jumbo und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Cancer antigen 15-3 (CA 15-3), a circulating epitope of mucin-1 (MUC1), is used principally to support monitoring of breast cancer, whereas complete blood count indices reflect inflammation, marrow function and treatment-related toxicity. Treatment exposure can alter both marker systems, so the relationship between them may differ according to treatment status, and Nigerian data are limited.
Aim
To determine the association between serum CA 15-3 and haematological parameters overall and within treatment exposed, newly diagnosed and healthy-control groups, and to describe CA 15-3 concentrations across the three groups.
Methods
A hospital-based cross-sectional case-control study at the University of Port Harcourt Teaching Hospital enrolled 120 Nigerian women: 40 treatment-exposed patients (TG), 40 newly diagnosed treatment-naive patients (NG) and 40 apparently healthy controls (HC). Serum CA 15-3 was measured by enzyme-linked immunosorbent assay and a complete blood count panel on an automated five-part differential analyser. CA 15-3 was compared across groups by the Kruskal-Wallis test with Holm-adjusted Mann-Whitney pairwise comparisons, with one-way analysis of variance reported as a supportive analysis. Associations between CA 15-3 and each haematological parameter were assessed with two-tailed Spearman rank correlations using pairwise-complete observations (approximately 60 pooled, approximately 20 per group), with Benjamini-Hochberg false-discovery-rate (FDR) correction within each analysis family.
Results
CA 15-3 differed among groups (H = 10.510, df = 2, p = 0.0052), with the highest median in newly diagnosed patients (158.50 U/mL; IQR 36.13-185.95) versus treatment-exposed patients (34.00; 14.85-121.05) and healthy controls (26.80; 22.98 30.75); only the newly diagnosed versus control contrast remained significant after Holm adjustment (p = 0.0019). In the pooled sample, CA 15-3 correlated positively with white cell count (WBC; ρ = 0.386; FDR p = 0.0433) and absolute neutrophil count (NEU#; ρ = 0.373; FDR p = 0.0433). Group-specific analysis concentrated these findings in treatment-exposed patients, in whom CA 15-3 correlated with NEU# (ρ = 0.654; FDR p = 0.0282), WBC (ρ = 0.644; FDR p = 0.0282) and red cell distribution width-CV (ρ = 0.622; FDR p = 0.0297). No correlation survived FDR correction in newly diagnosed patients or healthy controls.
Conclusion
The pooled CA 15-3 associations with leucocyte and neutrophil counts were concentrated in treatment-exposed patients, whereas CA 15-3 concentrations were highest in newly diagnosed patients. Treatment status should be considered when interpreting CA 15-3 alongside routine blood-count indices. The findings are exploratory given the small group-specific samples and require confirmation in larger longitudinal studies.
Zitieren
APA
Jumbo, M. I., Bartimaeus, E. S., Eze, E. M., & Jeremiah, Z. A. (2026). Association Between Cancer Antigen 15-3 and Haematological Parameters According to Treatment Status in Nigerian Women With Breast Cancer. Current Research in Health Sciences, 4(2), 48. https://doi.org/10.58613/crhs427
Vancouver
Jumbo MI, Bartimaeus ES, Eze EM, Jeremiah ZA. Association Between Cancer Antigen 15-3 and Haematological Parameters According to Treatment Status in Nigerian Women With Breast Cancer. Current Research in Health Sciences. 2026;4(2):48. doi:10.58613/crhs427
BibTeX
@article{Jumbo2026,
author = {Jumbo, Mieiwari Ibifubara and Bartimaeus, Ebirien-Agana Samuel and Eze, Evelyn Mgbeoma and Jeremiah, Zaccheaus Awortu},
title = {Association Between Cancer Antigen 15-3 and Haematological Parameters According to Treatment Status in Nigerian Women With Breast Cancer},
journal = {Current Research in Health Sciences},
year = {2026},
volume = {4},
number = {2},
pages = {48},
doi = {10.58613/crhs427}
}
EUVIMED